Twitter Logo Youtube Circle Icon LinkedIn Icon

United Kingdom > London > TMT (technology, media and telecoms) > Pharmaceuticals and biotechnology > Law firm and leading lawyer rankings

Editorial

Other

Index of tables

  1. Pharmaceuticals and biotechnology
  2. Leading individuals
  3. Next generation lawyers

Leading individuals

  1. 1

Next generation lawyers

  1. 1

Who Represents Who

Find out which law firms are representing which Pharmaceuticals and biotechnology clients in London using The Legal 500's new comprehensive database of law firm/client relationships. Instantly search over 925,000 relationships, including over 83,000 Fortune 500, 46,000 FTSE350 and 13,000 DAX 30 relationships globally. Access is free for in-house lawyers, and by subscription for law firms. For more information, contact david.burgess@legal500.com.

CLICK HERE TO VISIT THE WHO REPRESENTS WHO SITE

IP and transactions are the key pillars of Allen & Overy LLP's practice. Jim Ford¬†leads the team and recently worked with Circassia Pharmaceuticals on its $230m arrangement with AstraZeneca regarding the development of two respiratory medicines: Tudorza and Duaklir. Other key members working on the transactions side include Matthew Appleton¬†and Richard Hough.¬†Appleton advised Gr√ľnenthal on its purchase of the rights to the migraine medication Zomig from AstraZeneca. On the IP side, Marjan Noor¬†has 'excellent client handling skills' and recently represented Eli Lily in defending revocation claims relating to patents of their erectile dysfunction drug¬†tadalafil. Mark Ridgway¬†is 'a great thinker' and 'never afraid to roll his sleeves up'. Also highly recommended are IP litigator¬†Neville Cordell;¬†Marc D√∂ring, who advised Bayer on patent infringement issues; and senior associate Rafi Allos, who is also experienced in patent litigation.¬†Nicola Dagg¬†joined¬†Kirkland & Ellis International LLP.

Arnold & Porter is particularly known for its work in regulatory and competition matters, and has additional expertise in patent litigation, product liability, and corporate and commercial matters. Ian Dodds-Smith leads the team and has notable strengths in regulatory and product liability matters. Adela Williams is also a key figure and is an expert in advising on clinical trials, marketing authorisations and promotional issues, and has additional expertise in dealing with product liability cases. Another notable name is Lincoln Tsang, who specialises in regulatory, compliance, enforcement and public policy issues. Also highly recommended are Jeremy Willcocks, of counsel Jacqueline Mulryne, Kathy Osgerby and Ewan Townsend. Tim Frazer has retired, while patent litigation partner Christopher Stothers left the firm for Freshfields Bruckhaus Deringer LLP alongside counsel Laura Whiting.

Bird & Bird LLP provides IP as well as corporate and commercial advice for clients such as Merck, ConvaTec and Amgen. Practice co-head Mark Hilton has extensive experience in patent litigation and provides 'strategic' and 'practical' advice'. He recently defended Actavis in its patent litigation with Eli Lilly regarding alleged infringement of the latter's anti-cancer drug pemetrexed disodium and, alongside Neil Jenkins, acted for Teva against Synthon which sought patent revocation actions against the client's MS drug glatiramer acetate. Sally Shorthose focuses on commercial and transactional IP and acted for Chiesi in its purchase of the rights to PROCYSBI and QUINSAIR from Horizon Pharma. Robert Williams is also an expert in patent law and adopts 'a pragmatic and solution-oriented approach to complex matters'. Morag Macdonald is 'a very good strategist who provides clear, practical advice' and is 'definitely someone you want on your side'. She represented Fisher & Paykel Healthcare in the revocation of three of ResMed's patents pertaining to the design of CPAP masks, which is used to treat sleep apnoea. Also recommended are Jennifer Jones, who represented Actavis in revoking two of Eli Lilly's patents relating to its erectile dysfunction drug Tadalafil, and patent litigator Tim Harris.

The 'excellent' and 'client-focused' Bristows LLP has a strong reputation in patent litigation, but also works on matters involving transactions, regulations and competition. The practice is headed by patent litigator Liz Cohen and transactions specialist Laura Anderson. Brian Cordery is head of patent litigation and very active in this space. He was instructed by Teva in patent revocation proceedings brought by Eli Lilly relating to humanised antibodies, which may be used for a landmark treatment of migraines. Other important  contentious IP specialists include Edward Nodder, Robert Burrows and Dominic Adair. Burrows defended Janssen Sciences and G.D. Searle against a revocation brought by Sandoz and Hexal relating to darunavir, which is a key ingredient in Janssen's anti-HIV drug Prezista. Also recommended are corporate specialist Marek Petecki, who assisted AstraZeneca with its $300m sale of the European commercial rights to its Seloken heart medication to Recordati, and senior associate Rachel Mumby, who focuses on patent litigation.

CMS' broad practice contains experts in the fields of corporate and commercial transactions, intellectual property, competition and product liability. Commercial transactions specialist Sarah Hanson jointly heads the team and is a particularly strong in life sciences joint ventures and collaborations. Other notable names for transactions include Carina Healy, Niall McAlister and Simon Morgan. McAlister advised SR One and Longwood on its Series B investment in Pulmocide. Fellow practice head Robert Stephen  is an expert in patent litigation. Other key figures on the IP side include Gareth Morgan, Richard Price and Sarah Wright . Notable names for product liability include Shuna Mason, Omar Qureshi and David Bridge. Also recommended are Brian Sher and Caroline Hobson, who are both experts in competition law. Sher represented GlaxoSmithKline in an appeal to the Competition Appeal Tribunal in relation to infringement findings and penalties brought by the CMA.

Herbert Smith Freehills LLP's repertoire in this area includes advising on transactions, patent litigation, dispute resolution and regulations. Sophie Rich and Sebastian Moore are two key figures in the patent litigation team. Rich represented AbbVie in its proceedings against Fujifilm Kyowa Kirin Biologics, Biogen and Samsung Bioepis regarding their infringement of the client's Humira drug, which is used to treat certain forms of arthritis. Moore defended Gilead against patent infringement allegations brought by Idenix in relation to its Hepatitis C treatment sofosbuvir. Regulatory issues are handled by Kyriakos Fountoukakos, who divides his time between the Brussels and London offices. Senior associate Jonathan Turnbull is also experienced in regulatory matters. On the transactions side, Alan Montgomery assisted Claris Lifesciences with its $625m sale of its specialty injectables business to Baxter International. Chris Parker focuses on contentious work and is an expert in international commercial arbitration.

Simmons & Simmons is 'jam-packed full of the highest-calibre individuals' in the areas of transactions, patent litigation and regulations. Michael Gavey leads the team and is particularly prominent in handling the IP aspects of transactions. Charles Mayo is also a key figure and highly experienced in M&A and capital markets transactions. Other key members of the team include Scott Parker, who is an expert in patent litigation, and transactions specialist Lydia Torne. Rowan Freeland has retired.

Baker McKenzie focuses on M&A, IP and regulatory work for clients such as Walgreens Boots Alliance and Novartis. Transactions expert Hiroshi Sheraton leads the team and advised Basilea on its licensing agreement with Pfizer for the rights to anti-fungal drug Cresemba. Jane Hobson also focuses on transactions and recently assisted ICU with its $900m purchase of Hospira. Product liability specialist John Leadley defended Bard against claims of allegedly faulty medical devices and procedures used to treat female pelvic organ prolapse and stress urinary incontinence. Other noteworthy names include Joanna Ludlam, who is an expert in public procurement; commercial agreements expert Duncan Reid-Thomas; and senior associate Julia Gillert, who is an expert in regulatory and compliance issues.

The 'excellent' Cooley (UK) LLP handles IP and transactional matters in this sector. The 'outstanding' John Wilkinson jointly heads the practice and has 'an encyclopaedic knowledge of life sciences and legal detail'. He has expertise in the areas of IP, regulatory, competition and transactions, and recently advised Addex on its collaboration with Individior with the aim of developing a product to treat addiction. Fellow practice head Nicola Maguire is an expert in non-contentious IP issues and assisted PhoreMost with licensing technology from the University of Turin. Patent attorney Colm Murphy defended Illumina against challenges to its patents after it acquired Solexa. Corporate transactions specialist Stephen Rosen advised Orchard Therapeutics on its $110m Series B financing from Baillie Gifford and ORI Capital. Corporate specialist Ed  Lukins is also recommended.

Life sciences regulations, patent litigation and corporate advice are the standout specialties of Fieldfisher in this sphere. The regulatory team is led by Alison Dennis, who is supported by John Cassels and associate Nicola Bex. Dennis worked with the administrators behind Redx Pharma and Redx Oncology on the disposal of its Redx BTK programme. Sarah Ellson jointly heads the healthcare regulatory team and acted for Roche in its appeal against a NICE appraisal that refused to extend the use of its Esbriet drug by the NHS. For patent litigation, Beatriz San Martin, Diana Sternfield, Nicole Jadeja, Rebecca Baines and David Knight are all key names. The team acted for GSK in a  patent dispute against Pfizer regarding Meningitis B vaccines. San Martin represented Sandoz, which sought a revocation of GD Searle's patent for darunavir, which is an antiretroviral used to treat HIV. Knight defended Lenstec against alleged patent infringement from its intraocular lenses. Corporate partners Neil Matthews and Dominic Gurney-Champion are also recommended.

Gowling WLG has a strong reputation in patent litigation and commercial arrangements and regularly acts for a number of heavyweight pharmaceutical and life sciences companies. Birmingham-based Patrick Duxbury is head of life sciences and an expert in advising on strategic collaborations. He advised AstraZeneca on its collaboration with Merck to develop and enhance oncology drugs and assisted MedImmune with its alliance with Sanofi Pasteur to develop and commercialise an antibody that prevents lower respiratory tract illness. Patent litigator Paul Inman represented Fujifilm Kyowa Kirin Biologics in its litigation against AbbVie with regard to the client wishing to produce a biosimilar of AbbVie's Humira drug. He also defended GSK against patent infringement proceedings brought by Vectura in relation to powders used in inhaler products. Another key figure is Luke Kempton, who  advised BIAL on a licensing agreement for the development and commercialisation of opicapone in North America. Also recommended is Ian Piggin, who worked with Epidarex Capital Management in its investment into IGEM Therapeutics, which focuses on Immunoglobulin E based biologics for cancer treatment.

Hogan Lovells International LLP has 'a truly global life sciences practice' with 'an impressive roster of household-name producer clients who know that they are guaranteed a Rolls-Royce service'. Matthew Felwick jointly heads  the life sciences team and is 'a particularly effective communicator', who 'has acted in many of the major life science product liability claims in the UK in recent years and is particularly popular with clients'. Fellow practice head Stephen Bennett is an expert in IP and recently acted for Eli Lilly in Supreme Court litigation against Actavis, whose generic version of the client's oncology product, Alimta, infringed upon the brand name drug. John Meltzer also focuses on contentious matters, but in the field of product liability, where he recently defended Zimmer Biomet against liability claims regarding its assessment of product conformity of breast implants with medical device safety standards. Also recommended is John Meltzer, who is 'one of the most widely respected lawyers in this field with unrivalled experience of major litigation'.

Pinsent Masons LLP is 'first class', 'super efficient' and 'always provides clear, concise and relevant advice'. Practice head Clare Tunstall is 'a leader in this field' and 'an astute and tactical litigator' with 'an impressive track record of success'. She recently represented Flynn in its challenge to prevent the parallel importation into the UK of Pfizer’s anti-epileptic drug Epanutin for resale as Phenytoin Sodium Flynn. Allistair Booth advised Summit Therapeutics on the IP and commercial elements of its purchase of Discuva. Patent litigator Charlotte Weekes is 'extremely thorough in her approach' and 'really adds value to the litigation team with her eye for the key points and for detail'. Fellow patent litigator Christopher Sharp is 'legally astute' with 'a strong understating of small and large molecule chemistry'. Also recommended is Charles Waddell, who is an expert in M&A and capital markets transactions, and Catherine Drew, who advised Accord Healthcare on the revocation of four patents protecting Celgene’s drug Revlimid, which is used to treat some forms of blood and bone marrow cancer.

Powell Gilbert LLP’s 'key advantage is its strength in depth' where 'although it isn’t a large firm, it has a very large number of very able lawyers of uniformly very high quality'. Patent litigator Penny Gilbert jointly heads the team and recently defended Biogen against actions brought by AbbVie in relation to the client's biosimilar of AbbVie’s drug Humira. Fellow practice head Tim Powell is also an expert in patent litigation and recently acted for Illumina, whose patented foetal diagnosis technology was allegedly infringed upon by Premaitha, The Doctors Laboratory and Ariosa Diagnostics. Other notable names include Bethan Hopewell, who acted for Actavis in its dispute with Warner Lambert regarding infringement upon the latter's drug Lyrica; Alex Wilson, who advised Vivagro on a contractual dispute with Oro Agri International; and Tim Whitfield, who acted for Napp in a patent infringement case against Sandoz, whose product infringed upon its analgesic transdermal buprenorphine patch product.

Taylor Wessing LLP's core ares of expertise include corporate, M&A, patent litigation, general disputes and regulatory matters. Malcolm Bates heads the life sciences team and recently assisted TxCell with its manufacturing agreement with Lentigen Technology. Tim Worden leads the regulatory group and is 'an excellent lawyer', 'very approachable and pragmatic', with 'a great working knowledge of the healthcare sector'. On the corporate side David Mardle is at the fore and is supported by Adrian Rainey, who advised Cambridge Innovation Capital on its £8m equity investment into the clinical genomics company Congenica. Nigel Stoate runs the patents team and represented the Pfizer subsidiary Hospira in its revocation against Cubist's patents involving the methods behind dosing and purifying daptomycin, which can be used to treat MRSA. Fellow patent litigator Matthew Royle is also recommended.

The team at Carpmaels & Ransford LLP provides 'excellent service', 'consistently wins big cases' and 'is very well prepared'. Hugh Goodfellow heads the life sciences team and recently represented Abraxis BioScience in its appeal against the UKIPO’s rejection of an SPC grant for Abraxane, which can be used to treat breast, lung and pancreatic cancer. Leading the dispute resolution team is Ian Kirby, who regularly acts on patent and trade mark disputes. Camilla Balleny is also an expert in patent litigation  and recently defended Celegene against three patent revocations relating to its top-selling drug Revlimid, which is used to treat multiple myeloma. Also working on patent disputes is David Wilson, who acted in two High Court patent infringement and revocation proceedings between his client PacBio and Oxford Nanopore Technologies, which allegedly infringed upon the client's DNA sequencing technology. Cameron Marshall worked with Merck on its appeal against Shionogi, which sought to revoke the client's anti-HIV integrase inhibitor ISENTRESS. Other key figures include Jake Marshall, who is head of transactions; James Warner, who leads the life sciences team; Mark Chapman, who heads the biotech life sciences group; and pharmaceuticals specialists Edward Oates.

Covington & Burling LLP  is also ranked.

DAC Beachcroft LLP is 'highly regarded' and has strong expertise in product liability and regulatory work. Simon Pearl and Alison MacAdams jointly lead the practice and both have 'tremendous analytical legal skills' with 'second-to-none experience in life science product and healthcare law'. BMI is a key client of Pearl's, which he advised on claims over the failure of metal hip replacements brought by 500 individuals. He also defended BMI on litigation concerning claims brought by silicone gel in breast implants manufactured by PIP. Recent work highlights for MacAdams include advising Optegra on the allegedly defective implantation of an intraocular lens, which was brought by a number of claimants. Bristol-based IP specialist Andrew Allan-Jones is also a key figure, as is associate Olya Melnitchouk, who is 'destined for great heights' and 'oozes efficiency and legal skill'.

IP, transactions and competition are the three key focal points for DLA Piper.  Bonella Ramsay leads the team and has expertise in IP, regulatory and contractual matters. Key figures from the IP side include Richard Taylor,  Claire Bennett and Ruth Hoy. Hoy recently assisted Kite Pharma with the management of its global trade mark portfolio. Bennett represented Novo Nordisk in patent litigation against Regeneron, which involved transgenic mice being used to create human monoclonal antibodies. She has additional expertise in competition law and acted for Merck KGaA in its appeal to the CAT with respect to the CMA’s fines of £45m, where it was alleged that the client paid drugmakers to delay the production of cheaper alternatives. Also recommended are employment expert Adam Hartley and merger control specialist Alexandra Kamerling.

Linklaters LLP's practice is divided into competition, corporate and TMT-related work, with Aisling Zarraga and Marly Didizian at the fore. Zarraga heads the corporate team and other key members include James Inglis and Matthew Bland. Didizian works at the helm of the TMT team with other notable names such as Ian Karet, Nigel Jones and Yohan Liyanage. Liyanage defended Regeneron and Sanofi in an appeal regarding the sale of the cholesterol drug Praluent due to patent infringement. Karet is acting for Merck & Co in its trade mark dispute with Merck KGaA regarding the Merck name. Key members of the competition team include Nicole Kar and Sir Christopher Bellamy.

Marks & Clerk Solicitors has a strong track record in patent litigation and a growing presence in the commercial field. Mike Gilbert heads the practice and has extensive experience in handling SPCs and patent rights. Patent litigator Will James is also a key figure and his 'combination of objectivity and passion makes him a fearsome practitioner in this sphere'. Graham Burnett-Hall, Charlie Balme and Gregor Grant are also experts in patent disputes. Also recommended are commercial IP experts Simon Portman and Michael Moore. Key mandates for the team included Gilbert, James and Moore defending Genentech against two actions from Eli Lilly: the first is to invalidate one of the client's patents and the second involved declarations of non-infringement of the same patent. Gilbert and Balme represented Chugai in a declaration of non-infringement in relation to its antibody Actemra. Gilbert and Hall acted for AstraZeneca against Astex Therapeutics, where Astex's  involvement in the development of a landmark new treatment for Alzheimer’s was contended.

Mills & Reeve LLP's team is led by James Fry, who joined in 2017 from Eversheds Sutherland (International) LLP . Fry's 'pharmaceutical and biotech sector expertise is first class' and he 'consistently provides sound, pragmatic advice'. He recently advised The Diurnal Group on its primary and secondary agreements for the supply chain it will be using for the production of two drug candidates. Another recent arrival is IP specialist Mark Pearce, who joined from Womble Bond Dickinson (UK) LLP. Other key members of the team include employment expert Melanie James; IP expert Alasdair Poore; and Zickie Lim, who is an expert in corporate finance. Lim advised PredictImmune on its syndicated financing from Cambridge Enterprise and the University of Cambridge.

Norton Rose Fulbright's multi-disciplined practice has a client roster which includes big names such as GlaxoSmithKline, Pfizer and Bayer. IP expert Huw Evans leads the team and recently defended Oxford Nanopore Technologies against patent infringement claims brought by Pacific Biosciencs of California regarding DNA sequencing technology. Michael (Mike) Knapper also works on IP matters, predominantly non-contentious, while Jonathan Ball focuses mainly on IP and technology disputes. Also recommended are corporate finance specialist Milana Chamberlain, product liability expert Caroline May and corporate lawyers Ian Lopez and Gareth Kendall.

Corporate, commercial, transactions and IP are the core areas of focus for Slaughter and May. Susie Middlemiss co-heads the team and has expertise in disputes and IP work. Fellow practice head David Johnson focuses on corporate and commercial transactions and assisted GlaxoSmithKline with the $619m sale of its 6.2% stake in Aspen Pharmacare. Alongside Johnson, corporate transactions expert Simon Nicholls worked with Actelion on its sale to Johnson & Johnson. Corporate and commercial law specialist Richard Smith advised Immunocore on its collaboration with the Bill & Melinda Gates Foundation, which will focus on developing treatments for HIV and TB using T-cell receptors.

Squire Patton Boggs 'delivers a high-quality, consistent, professional service' and has expertise in advising on commercial, regulatory and intellectual property issues. Andrew Wilkinson heads the team and is an expert in commercial matters. Consultant Adrian Spooner is also a key figure and has 'a well-rounded understanding of the life sciences sector' and 'strong insight into critical change scenarios, such as Brexit impacts'. Senior associate Paul Jinks and associate James Pearson are also names of note.

Ashurst¬†has strong expertise in the areas of corporate finance and intellectual property.¬†Private equity partner Nick Rainsford¬†handled¬†LGC's sale of its Forensics and Security division to Eurofins Scientific.¬†Corporate specialist Eric Stuart advised Jefferies as bookrunner regarding Kiadis Pharma's placement of 2.25 million new shares with institutional investors for ‚ā¨18m. Mark Lubbock¬†has joined Brown Rudnick LLP¬†.

Clyde & Co LLP has expertise in the fields of corporate, commercial, IP and product liability. Corporate and commercial specialist Simon Gamblin leads the team alongside Ralph Cox, who is an expert in patent litigation. Product liability specialist Claire Petts is also a key figure and advised CNA Hardy and ITH Pharma on a product liability claim relating to contaminated baby feed. Other notable names include Simon Vere Nicoll, who advises on corporate transactions; legal director Erika Rainger, who is an expert in product liability; and legal director Don McCombie, who specialises in transactional and regulatory issues.

Dechert LLP's cross-department life sciences team handles M&A, financing, capital markets and regulatory matters. Practice head Graham Defries specialises in transactions; he advised Bicycle Therapeutics Limited on its £40m Series B equity financing round and assisted Biocon with its collaboration with Sandoz towards the development of biosimilars in the fields of immunocology and oncology. Also recommended are cross-border transactions expert Andrew Harrow, and Patrick Lyons, who specialises in capital markets transactions.

Freshfields Bruckhaus Deringer LLP's global healthcare team is led by¬† London-based Jennifer Bethlehem, who regularly advises on big-ticket M&A deals in this space. She recently advised¬†Merck KGaA on the ‚ā¨3.4bn sale of its global consumer health company to Procter & Gamble.¬†Also recommended are product liability specialists Jonathan Isted¬†and Andrew Austin. The firm hired a patent litigation team from Arnold & Porter¬† led by partner Christopher Stothers¬†and counsel Laura Whiting¬†.

Hempsons is led by James Lawford Davies, who is an expert in life sciences regulation and litigation. Recent mandates for Lawford Davies include advising the Francis Crick Institute (and The Wellcome Trust) on obtaining regulatory approval for its gene editing technology, and defending Professor Paolo Macchiarini, who was accused of research misconduct following the death of a patient and falsifying academic credentials. Also recommended are corporate and commercial specialists Jamie Foster and Faisal Dhalla, as well as IP expert Gill Hall.

Patent litigation and M&A are the two main areas where Jones Day operates in this space. Patent litigator Alastair McCulloch is a key figure and 'has very deep experience', 'pays a lot of attention to detail', 'is strong on the technological aspects of his cases', and 'really works to understand his clients'. Also recommended is Leon Ferera, who regularly advises on life sciences transactions.

Marriott Harrison LLP focuses predominantly on regulatory matters, and provides 'first-rate response times' and 'value for money'. Alexander Denoon has 'excellent commercial judgement' and is 'extremely knowledgeable on non-transactional life sciences law'. Julian Hitchcock is also recommended and highly experienced in regulatory issues.

IP disputes and regulatory issues are the key areas of focus for Mishcon de Reya LLP, with clients that include Pfizer, Sanofi and GlaxoSmithKline. Martyn Hann heads the practice and advised Hempshire on the regulatory aspects of its growth of cannabis; the client uses extracts from the plant for healthcare products. David Rose is an expert in intellectual property disputes and recently represented Lupin, which sought a revocation against Gilead's SPC for its HIV treatment product, Truvada. He also defended Dr Reddy’s Laboratories against Pfizer, which alleged that the client infringed upon its Lyrica drug.

Morgan, Lewis & Bockius UK LLP's skill set in this space is primarily in transactional and regulatory matters, with Tom Cartwright and Tim Corbett at the fore. Cartwright is particularly known for his work on M&A and private equity transactions, and Corbett is an expert in capital raising. Corbett recently advised  uniQure N.V. on its public offering of ordinary shares and Nasdaq listing as well as assisted Replimune with its corporate reorganisation and Series B preferred stock financing. Consultant Paul Ranson specialises in regulatory issues pertaining to the fields of pharmaceuticals, biotechnology, and medical devices. Frances Murphy defended Concordia against investigations by the CMA in relation to alleged market-sharing and unfair pricing, and also advised Sanofi-Aventis on competition issues. Matthew Howse worked with Integra on the employment law elements on its acquisition of Codman from Johnson & Johnson. Omar Shah, Paulina Whitaker and Stephen Walters are also highly recommended.

Osborne Clarke LLP's presence in this space stems from its transactional and intellectual property work. Transactions expert and team head Janita Good advised Takeda Ventures on its IPO investment in Arix Bioscience and assisted Millennium Pharmaceuticals with its purchase of GammaDelta Therapeutics. Other noteworthy names include Lorna Brazell, who heads the patent litigation team, and competition experts Simon Neill and Marc Shrimpling.

RPC provides an 'extremely high level of service and support' in product liability claims. Team head Dorothy Flower recently advised Clover Leaf Products, a former distributor of PIP breast implants which were later deemed faulty. Also recommended is Peter Rudd-Clarke, who is 'very calm, honest, knowledgeable, organised and efficient'.

Sidley Austin LLP  is also recommended.

The 'excellent', 'very pragmatic' and 'professional' Stephenson Harwood focuses on intellectual property and corporate matters in this space. Corporate partner Andrew Edge jointly heads heads the team and recently advised Novacyt on its dual listing on the London Stock Exchange and Euronext Paris. Another key name on the corporate side is Anthony Clare, who assisted Acacia Pharma with its listing on Euronext Brussels. Team co-head Alexandra Pygall specialises in IP and is 'highly knowledgeable in this field'. For contentious matters, her litigation strategy is 'excellent' and she is also 'highly effective' in mediation. Rob Jacob is another key member of the IP team, with notable strengths in trade mark work. Also recommended is senior associate Eibhlin Vardy, who is experienced in patent litigation.

Stevens & Bolton LLP's multi-disciplined practice covers IP, commercial, competition and disputes matters. Charlotte Tillett leads the team and has extensive experience in both contentious and non-contentious intellectual property matters. Tom Lingard heads the IP team and is also heavily involved in this sector. Michael Frisby is an expert in life sciences-related disputes, both litigation and arbitration. Commercial lawyer Beverley Flynn advised SecurMed UK on its arrangement with Arvato Systems to establish a medicines verification system for the prescription and supply of medicines in the UK. Construction specialist Stephen Rockhill assisted Institute for Cancer Research with the documentation behind the construction of a new laboratory. Also recommended is competition expert Gustaf Duhs, who worked with the British Generic Manufacturers Association on its application to intervene in the case where the Competition Market Authority fined Pfizer and Flynn for hiking prices of drugs supplied to the NHS.

Wiggin LLP contains the former IP team of Redd Solicitors, which the firm merged with in 2017. IP litigator Sara Ashby is a key figure, with a strong skill set in advising on disputes pertaining to designs, patents and parallel imports. Another notable name is Anna Carboni, who is known for her work on soft IP disputes and has additional expertise in patent law. Also recommended is Simon Chalkley, who has extensive experience in IP transactions.

Interview with...

Law firm partners and practice heads explain how their firms are adapting to clients' changing needs

International comparative guides

Giving the in-house community greater insight to the law and regulations in different jurisdictions.

Select Practice Area

GC Diversity and Inclusion Report

In partnership with...

Press releases

The latest news direct from law firms. If you would like to submit press releases for your firm, send an email request to

Legal Developments in London for Pharmaceuticals and biotechnology

Legal Developments in the UK

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to

Press Releases in the UK

The latest news direct from law firms. If you would like to submit press releases for your firm, send an email request to